134 related articles for article (PubMed ID: 31884896)
1. Idelalisib induces apoptosis in the lymphoid tissues and impairs lung function in mice.
George JA; Alshebli Z; Alneyadi A; Al Mukhaini N; Al-Salam S; Sudhadevi M; Souid AK; Alsuwaidi AR
J Chemother; 2020 Apr; 32(2):88-97. PubMed ID: 31884896
[TBL] [Abstract][Full Text] [Related]
2. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
3. The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
Chellappa S; Kushekhar K; Munthe LA; Tjønnfjord GE; Aandahl EM; Okkenhaug K; Taskén K
J Immunol; 2019 Mar; 202(5):1397-1405. PubMed ID: 30692213
[TBL] [Abstract][Full Text] [Related]
4. The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.
Rohrbacher L; Brauchle B; Ogrinc Wagner A; von Bergwelt-Baildon M; Bücklein VL; Subklewe M
Front Immunol; 2021; 12():608625. PubMed ID: 33790890
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies.
Kim YS; Cheon MG; Boggu PR; Koh SY; Park GM; Kim G; Park SH; Park SL; Lee CW; Kim JW; Jung YH
Bioorg Med Chem; 2021 Sep; 45():116312. PubMed ID: 34332211
[TBL] [Abstract][Full Text] [Related]
7. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
Stock S; Übelhart R; Schubert ML; Fan F; He B; Hoffmann JM; Wang L; Wang S; Gong W; Neuber B; Hückelhoven-Krauss A; Gern U; Christ C; Hexel M; Schmitt A; Schmidt P; Krauss J; Jäger D; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2019 Sep; 145(5):1312-1324. PubMed ID: 30737788
[TBL] [Abstract][Full Text] [Related]
8. Idelalisib Rescues Natural Killer Cells from Monocyte-Induced Immunosuppression by Inhibiting NOX2-Derived Reactive Oxygen Species.
Akhiani AA; Hallner A; Kiffin R; Aydin E; Werlenius O; Aurelius J; Martner A; Thorén FB; Hellstrand K
Cancer Immunol Res; 2020 Dec; 8(12):1532-1541. PubMed ID: 32967913
[TBL] [Abstract][Full Text] [Related]
9. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
Hanna BS; Roessner PM; Scheffold A; Jebaraj BMC; Demerdash Y; Öztürk S; Lichter P; Stilgenbauer S; Seiffert M
Leukemia; 2019 Jun; 33(6):1427-1438. PubMed ID: 30573773
[TBL] [Abstract][Full Text] [Related]
10. Idelalisib inhibits osteoclast differentiation and pre-osteoclast migration by blocking the PI3Kδ-Akt-c-Fos/NFATc1 signaling cascade.
Yeon JT; Kim KJ; Son YJ; Park SJ; Kim SH
Arch Pharm Res; 2019 Aug; 42(8):712-721. PubMed ID: 31161369
[TBL] [Abstract][Full Text] [Related]
11. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ.
Somoza JR; Koditek D; Villaseñor AG; Novikov N; Wong MH; Liclican A; Xing W; Lagpacan L; Wang R; Schultz BE; Papalia GA; Samuel D; Lad L; McGrath ME
J Biol Chem; 2015 Mar; 290(13):8439-46. PubMed ID: 25631052
[TBL] [Abstract][Full Text] [Related]
12. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.
Yang Q; Chen LS; Ha MJ; Do KA; Neelapu SS; Gandhi V
Clin Cancer Res; 2017 Jan; 23(1):181-192. PubMed ID: 27342398
[TBL] [Abstract][Full Text] [Related]
13. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Lim EL; Cugliandolo FM; Rosner DR; Gyori D; Roychoudhuri R; Okkenhaug K
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875319
[TBL] [Abstract][Full Text] [Related]
14. Effect of parenteral glutamine supplementation combined with enteral nutrition on Hsp90 expression and lymphoid organ apoptosis in severely burned rats.
Fan J; Wu J; Wu LD; Li GP; Xiong M; Chen X; Meng QY
Burns; 2016 Nov; 42(7):1494-1506. PubMed ID: 27613477
[TBL] [Abstract][Full Text] [Related]
15. Integrated molecular modeling techniques to reveal selective mechanisms of inhibitors to PI3Kδ with marketed Idelalisib.
Zhu J; Jia L; Jiang Y; Yu Q; Xu L; Cai Y; Chen Y; Li H; Gang H; Liang W; Jin J
Chem Biol Drug Des; 2021 Jun; 97(6):1158-1169. PubMed ID: 33657663
[TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis with fusarenon-X in mouse thymocytes.
Miura K; Nakajima Y; Yamanaka N; Terao K; Shibato T; Ishino S
Toxicology; 1998 May; 127(1-3):195-206. PubMed ID: 9699806
[TBL] [Abstract][Full Text] [Related]
17. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Chen Y; Zhou Q; Zhang L; Wang R; Jin M; Qiu Y; Kong D
Oncol Rep; 2016 Dec; 36(6):3643-3650. PubMed ID: 27748929
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib.
Bashash D; Safaroghli-Azar A; Dadashi M; Safa M; Momeny M; Ghaffari SH
Int J Biochem Cell Biol; 2017 Apr; 85():149-158. PubMed ID: 28254430
[TBL] [Abstract][Full Text] [Related]
19. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
20. The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells.
Braun C; Schlaweck S; Daecke SN; Brossart P; Heine A
Cancer Immunol Immunother; 2021 Dec; 70(12):3693-3700. PubMed ID: 34173009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]